A Severe Course of Relapsing-Remitting Acute-Onset Chronic Inflammatory Demyelinating Polyneuropathy in a Young Man
Acute-onset chronic inflammatory demyelinating polyneuropathy (A-CIDP) is an immune mediated neuropathy characterized by progressive weakness and sensory impairment lasting over 2 months. Guillain-Barré-Strohl syndrome (GBS) is an immune mediated polyneuropathy with a similar presentation often over...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2021-02-01
|
Series: | Case Reports in Neurology |
Subjects: | |
Online Access: | https://www.karger.com/Article/FullText/511956 |
id |
doaj-7e14884c982742a3b629f42428b61385 |
---|---|
record_format |
Article |
spelling |
doaj-7e14884c982742a3b629f42428b613852021-02-25T13:45:03ZengKarger PublishersCase Reports in Neurology1662-680X2021-02-01131737710.1159/000511956511956A Severe Course of Relapsing-Remitting Acute-Onset Chronic Inflammatory Demyelinating Polyneuropathy in a Young ManAnna P. PatnaikJoseph MininniNeil C. PorterNicholas A. MorrisAcute-onset chronic inflammatory demyelinating polyneuropathy (A-CIDP) is an immune mediated neuropathy characterized by progressive weakness and sensory impairment lasting over 2 months. Guillain-Barré-Strohl syndrome (GBS) is an immune mediated polyneuropathy with a similar presentation often over less than 4 weeks. While some have argued for the existence of recurrent GBS, most classify the syndrome as a form of relapsing-remitting CIDP. However, there are cases of GBS with treatment-related fluctuations that must be distinguished from A-CIDP as patients with A-CIDP require long-term immunotherapy. In this case report, we discuss a patient with multiple relapses over 3 years, who is more likely to have A-CIDP. His ganglioside profile, which has rarely been reported in A-CIDP, included high concentrations of anti-GM1, anti-GD1a, and anti-GD1b antibodies, which may account for his severe disease course.https://www.karger.com/Article/FullText/511956chronic inflammatory demyelinating polyneuropathyguillain-barré syndromedemyelinating polyneuropathy |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Anna P. Patnaik Joseph Mininni Neil C. Porter Nicholas A. Morris |
spellingShingle |
Anna P. Patnaik Joseph Mininni Neil C. Porter Nicholas A. Morris A Severe Course of Relapsing-Remitting Acute-Onset Chronic Inflammatory Demyelinating Polyneuropathy in a Young Man Case Reports in Neurology chronic inflammatory demyelinating polyneuropathy guillain-barré syndrome demyelinating polyneuropathy |
author_facet |
Anna P. Patnaik Joseph Mininni Neil C. Porter Nicholas A. Morris |
author_sort |
Anna P. Patnaik |
title |
A Severe Course of Relapsing-Remitting Acute-Onset Chronic Inflammatory Demyelinating Polyneuropathy in a Young Man |
title_short |
A Severe Course of Relapsing-Remitting Acute-Onset Chronic Inflammatory Demyelinating Polyneuropathy in a Young Man |
title_full |
A Severe Course of Relapsing-Remitting Acute-Onset Chronic Inflammatory Demyelinating Polyneuropathy in a Young Man |
title_fullStr |
A Severe Course of Relapsing-Remitting Acute-Onset Chronic Inflammatory Demyelinating Polyneuropathy in a Young Man |
title_full_unstemmed |
A Severe Course of Relapsing-Remitting Acute-Onset Chronic Inflammatory Demyelinating Polyneuropathy in a Young Man |
title_sort |
severe course of relapsing-remitting acute-onset chronic inflammatory demyelinating polyneuropathy in a young man |
publisher |
Karger Publishers |
series |
Case Reports in Neurology |
issn |
1662-680X |
publishDate |
2021-02-01 |
description |
Acute-onset chronic inflammatory demyelinating polyneuropathy (A-CIDP) is an immune mediated neuropathy characterized by progressive weakness and sensory impairment lasting over 2 months. Guillain-Barré-Strohl syndrome (GBS) is an immune mediated polyneuropathy with a similar presentation often over less than 4 weeks. While some have argued for the existence of recurrent GBS, most classify the syndrome as a form of relapsing-remitting CIDP. However, there are cases of GBS with treatment-related fluctuations that must be distinguished from A-CIDP as patients with A-CIDP require long-term immunotherapy. In this case report, we discuss a patient with multiple relapses over 3 years, who is more likely to have A-CIDP. His ganglioside profile, which has rarely been reported in A-CIDP, included high concentrations of anti-GM1, anti-GD1a, and anti-GD1b antibodies, which may account for his severe disease course. |
topic |
chronic inflammatory demyelinating polyneuropathy guillain-barré syndrome demyelinating polyneuropathy |
url |
https://www.karger.com/Article/FullText/511956 |
work_keys_str_mv |
AT annappatnaik aseverecourseofrelapsingremittingacuteonsetchronicinflammatorydemyelinatingpolyneuropathyinayoungman AT josephmininni aseverecourseofrelapsingremittingacuteonsetchronicinflammatorydemyelinatingpolyneuropathyinayoungman AT neilcporter aseverecourseofrelapsingremittingacuteonsetchronicinflammatorydemyelinatingpolyneuropathyinayoungman AT nicholasamorris aseverecourseofrelapsingremittingacuteonsetchronicinflammatorydemyelinatingpolyneuropathyinayoungman AT annappatnaik severecourseofrelapsingremittingacuteonsetchronicinflammatorydemyelinatingpolyneuropathyinayoungman AT josephmininni severecourseofrelapsingremittingacuteonsetchronicinflammatorydemyelinatingpolyneuropathyinayoungman AT neilcporter severecourseofrelapsingremittingacuteonsetchronicinflammatorydemyelinatingpolyneuropathyinayoungman AT nicholasamorris severecourseofrelapsingremittingacuteonsetchronicinflammatorydemyelinatingpolyneuropathyinayoungman |
_version_ |
1724251530381492224 |